Valeant's dose of reality - a podcast by Financial Times

Valeant was once considered a runaway success story, and one that upended the pharmaceutical sector. A series of crises engulfed the company in recent months, slashing nearly two thirds off its market valuation and forcing the company to tear up its forecasts for 2016. Correspondent David Crow explains. Read the full story at ft.com/valeant.Music: "Brand New Record!" by Steve Combs

---

See acast.com/privacy for privacy and opt-out information.

Further episodes of FT News in Focus

Further podcasts by Financial Times

Website of Financial Times